Abeona Therapeutics Inc (ABEO)
2.71
+0.28
(+11.52%)
USD |
NASDAQ |
Mar 24, 16:00
2.70
-0.01
(-0.37%)
After-Hours: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 46.37M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -68.28% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 3.009 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 99.58% |
News
Headline
Wire
Time (ET)
Globe Newswire
03/16 07:30
MT Newswires
11/08 11:45
MT Newswires
11/03 15:20
Yahoo
11/03 12:44
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 03/31/2023* | 08:30 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
| 03/31/2023* | -- | Results | Q4 2022 | -- | -0.74 | -- | |
| 08/11/2022 | 08:30 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 08/11/2022 | -- | Results | Q2 2022 | -2.08 | -0.68 | -208.1% | |
| 05/17/2022 | 08:30 EST | Earnings Call | Q1 2022 | -- | -- | -- | |
| 05/13/2022 | -- | Results | Q1 2022 | -3.50 | -3.25 | -7.69% | |
| 03/31/2022 | 08:30 EST | Earnings Call | Q4 2021 | -- | -- | -- | |
| 03/31/2022 | -- | Results | Q4 2021 | -11.25 | -3.92 | -187.2% |
*Estimated Date/Time
Earnings
Profile
Edit
| Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its lead clinical programs consist of EB-101, autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, adeno-associated virus-based gene therapy for Sanfilippo syndrome type A, and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. |
| URL | http://www.abeonatherapeutics.com |
| Investor Relations URL | N/A |
| HQ State/Province | New York |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Mar. 31, 2023 (est.) |
| Last Earnings Release | Aug. 11, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0.00% |
| Forward Yield | -- |
| Payout Ratio | -- |
| Cash Payout Ratio | -- |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 23, 2023.
Fundamentals
| Revenue (TTM) | -- |
| Total Expenses (TTM) | 51.80M |
| Net Income (TTM) | -85.25M |
| Total Assets (Quarterly) | 38.76M |
| Total Liabilities (Quarterly) | 23.35M |
| Shareholders Equity (Quarterly) | 15.41M |
| Cash from Operations (TTM) | -59.75M |
| Cash from Investing (TTM) | 9.325M |
| Cash from Financing (TTM) | 16.74M |
Ratings
Profile
Edit
| Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its lead clinical programs consist of EB-101, autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, adeno-associated virus-based gene therapy for Sanfilippo syndrome type A, and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. |
| URL | http://www.abeonatherapeutics.com |
| Investor Relations URL | N/A |
| HQ State/Province | New York |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Mar. 31, 2023 (est.) |
| Last Earnings Release | Aug. 11, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| ABEO Tweets |